GREM1 and Miyoshi myopathy: However, loss of DRM/Gremlin expression was observed in 12/15 (80%) of NSCLC cell lines, 5/13 (38%) of SCLC cell lines, 5/10 (50%) of breast cancer cell lines, and 4/6 (67%) of MM cell lines (Table 1 and Figure 2).